• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by CeriBell Inc.

    2/24/26 5:00:11 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CBLL alert in real time by email
    S-8 1 cbll-20260224.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on February 24, 2026

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    CeriBell, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware

     

    47-1785452

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

     

    360 N. Pastoria Avenue

    Sunnyvale, California

     

    94085

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    CeriBell, Inc. 2024 Incentive Award Plan

    CeriBell, Inc. 2024 Employee Stock Purchase Plan

    (Full Title of the Plan)

    Jane Chao, Ph.D.

    President, Chief Executive Officer, and Co-Founder

    CeriBell, Inc.

    360 N. Pastoria Avenue

    Sunnyvale, California 94085

    (800) 436-0826

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Louisa Daniels, Esq.

    Yawen Du, Esq.

    CeriBell, Inc.
    360 N. Pastoria Avenue

    Sunnyvale, California 94085

    (800) 436-0826

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

     

    ☐

     

    Accelerated filer

     

    ☐

     

     

     

     

    Non-accelerated filer

     

    ☒

     

    Smaller reporting company

     

    ☒

     

     

     

     

     

     

     

     

    Emerging growth company

     

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    REGISTRATION OF ADDITIONAL SHARES
    PURSUANT TO GENERAL INSTRUCTION E OF FORM S-8

     

    EXPLANATORY NOTE

     

    CeriBell, Inc., a Delaware corporation (the “Registrant”), is filing this Registration Statement on Form S-8 to register an additional 2,249,088 shares of its common stock, par value $0.001 (“Common Stock”) issuable under the Registrant's (i) 2024 Incentive Award Plan (the “2024 Plan”) and (ii) 2024 Employee Stock Purchase Plan (the “ESPP”). As a result of the operation of annual increase provisions therein, 1,874,240 shares of common stock were added to the 2024 Plan and 374,848 shares of common stock were added to the ESPP.

     

    The Registrant previously registered shares of its Common Stock for issuance under the 2024 Plan and the ESPP on Registration Statements on Form S-8 filed with the U.S. Securities and Exchange Commission (the “Commission”) on October 11, 2024 (File No. 333-282603) and on February 25, 2025 (File No. 333-285239) (collectively, the “Prior Registration Statements”). The Prior Registration Statements are currently effective. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E of Form S-8 regarding the “Registration of Additional Securities.”

     

    Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements relating to the 2024 Plan and the ESPP, including periodic reports that the Registrant filed after the Prior Registration Statements to maintain current information about the Registrant, are incorporated herein by reference and made part of this Registration Statement, except to the extent supplemented, superseded, or modified by the specific information set forth below and/or the specific exhibits attached hereto.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Not required to be filed with this Registration Statement.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

     

     

     

     

     

     

     

     

     

     

    Exhibit

     

    Exhibit Description

     

    Incorporated by Reference

     

    Filed

    Number

     

     

    Form

     

    Date

     

    Number

     

    Herewith

    4.1

     

    Amended and Restated Certificate of Incorporation

     

    8-K

     

    10/15/24

     

    3.1

     

     

    4.2

     

    Amended and Restated Bylaws

     

    8-K

     

    10/15/24

     

    3.2

     

     

    4.3

     

    Form of Common Stock Certificate.

     

    S-1/A

     

    9/19/24

     

    4.01

     

     

    5.1

     

    Opinion of Latham & Watkins LLP.

     

     

     

     

     

     

     

    X

    23.1

     

    Consent of Latham & Watkins LLP (included in Exhibit 5.1).

     

     

     

     

     

     

     

    X

    23.2

     

    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.

     

     

     

     

     

     

     

    X

    24.1

     

    Power of Attorney. Reference is made to the signature page to the Registration Statement.

     

     

     

     

     

     

     

    X

    99.1#

     

    2024 Incentive Award Plan.

     

    S-1/A

     

    10/7/24

     

    10.14

     

     

    99.2#

     

    Form of Agreements under 2024 Incentive Award Plan.

     

    S-1/A

     

    10/7/24

     

    10.15

     

     

    99.3#

     

    2024 Employee Stock Purchase Plan.

     

    S-1/A

     

    10/7/24

     

    10.16

     

     

    107

     

    Calculation of Filing Fee Table.

     

     

     

     

     

     

     

    X

     

    #  Indicates management contract or compensatory plan.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Sunnyvale, State of California, on this 24th day of February, 2026.

    CeriBell, Inc.

     

     

    By:

     

    /s/ Xingjuan (Jane) Chao, Ph.D.

     

     

    Xingjuan (Jane) Chao, Ph.D.

     

     

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Xingjuan (Jane) Chao, Ph.D., Scott Blumberg, and Louisa Daniels, and each of them, with full power of substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

    /s/ Xingjuan (Jane) Chao, Ph.D.

    Xingjuan (Jane) Chao, Ph.D.

     

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

     

    February 24, 2026

     

     

     

    /s/ Scott Blumberg

    Scott Blumberg

     

    Chief Financial Officer

    (Principal Financial Officer)

     

    February 24, 2026

     

     

     

    /s/ David Foehr

    David Foehr

     

    Senior Vice President, Finance

    (Principal Accounting Officer)

     

    February 24, 2026

     

     

     

    /s/ Rebecca Robertson

    Rebecca Robertson

     

    Chair of the Board of Directors

     

    February 24, 2026

     

     

     

    /s/ Juliet Tammenoms Bakker

    Juliet Tammenoms Bakker

     

    Director

     

    February 24, 2026

     

     

     

    /s/ William W. Burke

    William W. Burke

     

    Director

     

    February 24, 2026

     

     

     

    /s/ Erica Rogers

    Erica Rogers

     

    Director

     

    February 24, 2026

     

     

     

    /s/ Joseph M. Taylor

    Joseph M. Taylor

     

    Director

     

    February 24, 2026

     

     

     

     

     

    /s/ Josef Parvizi

     

    Director

     

    February 24, 2026

    Josef Parvizi, M.D., Ph.D.

     

     

     

     


    Get the next $CBLL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBLL

    DatePrice TargetRatingAnalyst
    10/21/2025$19.00Strong Buy
    Raymond James
    6/24/2025$30.00Buy
    BTIG Research
    4/4/2025$32.00Buy
    Ladenburg Thalmann
    11/5/2024$32.00Buy
    BofA Securities
    11/5/2024$30.00Buy
    Canaccord Genuity
    11/5/2024$32.00Overweight
    JP Morgan
    11/5/2024$31.00Buy
    TD Cowen
    11/5/2024Outperform
    William Blair
    More analyst ratings

    $CBLL
    SEC Filings

    View All

    SEC Form S-8 filed by CeriBell Inc.

    S-8 - Ceribell, Inc. (0001861107) (Filer)

    2/24/26 5:00:11 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by CeriBell Inc.

    10-K - Ceribell, Inc. (0001861107) (Filer)

    2/24/26 4:36:48 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CeriBell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Ceribell, Inc. (0001861107) (Filer)

    2/24/26 4:23:27 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on CeriBell with a new price target

    Raymond James initiated coverage of CeriBell with a rating of Strong Buy and set a new price target of $19.00

    10/21/25 7:19:41 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on CeriBell with a new price target

    BTIG Research initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00

    6/24/25 8:00:31 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ladenburg Thalmann initiated coverage on CeriBell with a new price target

    Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

    4/4/25 8:27:23 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results

    SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 & Recent Highlights Reported total revenue of $24.8 million in the fourth quarter of 2025, a 34% increase compared to the same period in 2024Delivered total revenue of $89.1 million for the full year of 2025, a 36% increase over the prior yearEnded the year with 647 total active accountsAchieved gross margin of 87% in the fourth quarter of 2025 and 8

    2/24/26 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell to Participate in Upcoming March Investor Conferences

    SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming investor conferences. Scott Blumberg, CFO, will present at the upcoming Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026, at 1:00 p.m. Pacific Standard Time / 4:00 p.m. Eastern Standard Time. Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming TD Cowen 46th Annual Health Care Conference on Tuesday, Marc

    2/18/26 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Tuesday, February 24, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 24, 2026. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing

    2/10/26 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tpg Gp A, Llc converted options into 3,587,154 shares and bought $6,464,556 worth of shares (380,268 units at $17.00) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    10/17/24 4:14:38 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Tammenoms Bakker Juliet was granted 6,618 shares, converted options into 2,140,600 shares and bought $4,032,978 worth of shares (237,234 units at $17.00) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    10/16/24 4:18:06 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Parvizi Josef sold $338,793 worth of shares (16,714 units at $20.27) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    2/23/26 12:07:59 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Parvizi Josef sold $165,720 worth of shares (8,286 units at $20.00) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    2/19/26 4:17:35 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    President and CEO Chao Xingjuan sold $786,240 worth of shares (39,000 units at $20.16) and exercised 25,000 shares at a strike of $4.70, decreasing direct ownership by 2% to 727,248 units (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    2/6/26 3:51:31 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Leadership Updates

    Live Leadership Updates

    View All

    Medtech Leader Erica Rogers Joins Ceribell Board of Directors

    SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies to Ceribell's Board as the Company executes on its mission to expand patient access to timely brain monitoring in the acute care setting. Ms. Rogers is an accomplished healthcare executive with board experience in both the public and private sectors. She most recently

    9/22/25 8:00:03 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing

    —Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell"), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. "Ms. Rodenbush and Mr. Price bring an impressive wealth of experience to Ceribell, and I am confident that their leadership across our People & Culture and Marketing fu

    11/19/24 8:00:00 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Financials

    Live finance-specific insights

    View All

    Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results

    SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 & Recent Highlights Reported total revenue of $24.8 million in the fourth quarter of 2025, a 34% increase compared to the same period in 2024Delivered total revenue of $89.1 million for the full year of 2025, a 36% increase over the prior yearEnded the year with 647 total active accountsAchieved gross margin of 87% in the fourth quarter of 2025 and 8

    2/24/26 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Tuesday, February 24, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on February 24, 2026. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing

    2/10/26 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell Reports Third Quarter 2025 Financial Results

    SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 & Recent Highlights Reported total revenue of $22.6 million in the third quarter of 2025, a 31% increase compared to the same period in 2024Achieved gross margin of 88% compared to 87% for the same period in 2024 Ended the quarter with 615 total active accounts Appointed Erica Rogers to the Board of Directors "We are encouraged by our third quarter performance, which re

    11/4/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CeriBell Inc.

    SC 13G - Ceribell, Inc. (0001861107) (Subject)

    11/7/24 9:24:55 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by CeriBell Inc.

    SC 13D - Ceribell, Inc. (0001861107) (Subject)

    10/22/24 4:20:26 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care